Leukemia & Lymphoma最新文献_第3页

Deranged cytokine levels are linked to cancer-related cognitive impairment in lymphoma patients receiving R-CHOP chemotherapy. 细胞因子水平的变化与接受 R-CHOP 化疗的淋巴瘤患者与癌症相关的认知障碍有关。

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-03-01 Epub Date: 2024-11-15 DOI: 10.1080/10428194.2024.2424373

Pinki Mishra, Dinesh Bhurani, Mohd Ashif Khan, Nidhi

{"title":"Deranged cytokine levels are linked to cancer-related cognitive impairment in lymphoma patients receiving R-CHOP chemotherapy.","authors":"Pinki Mishra, Dinesh Bhurani, Mohd Ashif Khan, Nidhi","doi":"10.1080/10428194.2024.2424373","DOIUrl":"10.1080/10428194.2024.2424373","url":null,"abstract":"Cancer-related cognitive impairment (CRCI) is a significant issue commonly observed following chemotherapy treatment. The study aimed to investigate the changes in cognitive function and their association with IL-6, IL-1β, and IL-10 levels before and after R-CHOP chemotherapy over six cycles. Seventy chemotherapy naïve, newly diagnosed lymphoma patients were enrolled. Cognitive functions and inflammatory cytokines were assessed at baseline (TP1), after 3rd cycle (TP2), and after 6th cycle (TP3). Patients, with mean age of 44.17 ± 13.67 years, showed significantly increased levels of IL-6 and IL-1β and decreased IL-10 levels over time (p < .001). On the Montreal Cognitive Assessment (MoCA), scores of domains such as executive functioning (p = .002), attention (p < .001), language (p < .001), recall (p = .005), and orientation (p < .001) significantly decreased post six cycles of R-CHOP chemotherapy. Correlation analysis at TP2 indicated a positive association between elevated IL-6 levels with a decrease in MoCA scores indicating a decline in cognitive function (ρ = 0.68, p < .001). At TP3, no association of MoCA scores with IL-6 and IL-1β was observed. Decreased IL-10 levels showed a weak association with decreased MoCA scores at TP2 and TP3 (ρ = 0.2, p = .09; for TP3, ρ = 0.16, p = .17), but this was not significant. In summary, the findings of the present study highlight significant cognitive decline and changes in inflammatory cytokine levels following six cycles of R-CHOP. Objective cognitive assessments may be done to detect CRCI in patients treated with R-CHOP.","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"516-528"},"PeriodicalIF":2.2,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142622844","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

FISH combined with RT-PCR facilitates classification of Chinese adult patients with B-other ALL through improved identification of ZNF384 rearrangement. FISH与RT-PCR相结合，通过更好地识别ZNF384重排，有助于对中国成年B型其他ALL患者进行分类。

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-03-01 Epub Date: 2024-11-09 DOI: 10.1080/10428194.2024.2426055

Qinlu Li, Shugang Xing, Heng Zhang, Xia Mao, Min Xiao, Ying Wang

{"title":"FISH combined with RT-PCR facilitates classification of Chinese adult patients with B-other ALL through improved identification of ZNF384 rearrangement.","authors":"Qinlu Li, Shugang Xing, Heng Zhang, Xia Mao, Min Xiao, Ying Wang","doi":"10.1080/10428194.2024.2426055","DOIUrl":"10.1080/10428194.2024.2426055","url":null,"abstract":"ZNF384 gene rearrangements are a distinct subtype of adult B cell acute lymphoblastic leukemia (B-ALL). We screened 46 B-other ALL patients for ZNF384 fusions using fluorescent in situ hybridization (FISH) and reverse transcription-polymerase chain reaction (RT-PCR). Clinical data, treatment response, and minimal residual disease (MRD) status were analyzed. Ten (21.7%) patients were ZNF384-r positive (nine by FISH, nine by RT-PCR, eight by both). FISH showed atypical signals, including 3' signal gain and 5' signal deletion. EP300 was the main fusion partner (n = 5). TAF15::ZNF384, SYNRG::ZNF384, CREBBP::ZNF384, and TCF3::ZNF384 fusions were found in one patient each; one case's partner gene is unknown. One patient was MRD-negative at the end of the first induction, lower than in patients without ZNF384-r. ZNF384-r incidence matched B-other ALL incidence in Chinese patients. Combined FISH and RT-PCR improved detection. ALL with ZNF384-r has unique features, and lower MRD-negative response may indicate a negative impact on traditional treatments.","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"507-515"},"PeriodicalIF":2.2,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142622957","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Sweet syndrome with multiorgan involvement exacerbated by gilteritinib. 吉特替尼加剧了多器官受累的斯威特综合征。

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-03-01 Epub Date: 2024-11-14 DOI: 10.1080/10428194.2024.2426061

Ana Jiménez-Sánchez, María Olivares-Guerrero, Mario Aparicio-Domínguez, Sonsoles Berenguer-Ruiz, Luis Miguel Juárez-Salcedo, Patricia Muñoz-Hernández, Fernando Gallardo, Beatriz Bellosillo, Mar Llamas-Velasco

引用次数: 0

Infections during novel myeloma therapies. 新型骨髓瘤疗法期间的感染。

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-03-01 Epub Date: 2024-11-18 DOI: 10.1080/10428194.2024.2428819

Alice J Liu, Monica A Slavin, Simon J Harrison, Benjamin W Teh

引用次数: 0

Avascular necrosis in older adolescents and adults with acute lymphoblastic leukemia treated with FRALLE protocols: a multicenter analysis of incidence, risk factors and morbidity.

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-02-27 DOI: 10.1080/10428194.2025.2470784

Michelle Tan, Masa Lasica, Vanessa Donati, Kirsty Rady, Meena Nagarethinam, Shaun Fleming, Anthony Schwarer, Andrew Grigg, Stephen B Ting

{"title":"Avascular necrosis in older adolescents and adults with acute lymphoblastic leukemia treated with FRALLE protocols: a multicenter analysis of incidence, risk factors and morbidity.","authors":"Michelle Tan, Masa Lasica, Vanessa Donati, Kirsty Rady, Meena Nagarethinam, Shaun Fleming, Anthony Schwarer, Andrew Grigg, Stephen B Ting","doi":"10.1080/10428194.2025.2470784","DOIUrl":"https://doi.org/10.1080/10428194.2025.2470784","url":null,"abstract":"Paediatric-inspired acute lymphoblastic leukaemia (ALL) regimens have led to improved leukaemic outcomes in adults. However, avascular necrosis (AVN) has emerged as a debilitating orthopaedic complication. AVN is likely multifactorial, with corticosteroids and asparaginase therapy playing key roles in its pathogenesis. We assessed the incidence and potential risk factors for AVN, in older adolescent and adult patients with ALL treated with the FRALLE-93 protocol across three Australian tertiary centres. AVN occurred in 24% of 59 patients, primarily affecting hip and knee joints. Diagnosis occurred at a median of 11.7 months from commencement of chemotherapy. No association was identified between AVN risk and sex, age, BMI, smoking status and vitamin D level. The majority of patients required orthopaedic intervention (64%). Approximately two thirds had chronic pain or impaired mobility. AVN risk in adult patients with ALL receiving FRALLE protocols appears at least comparable to rates reported in paediatric cohorts.","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1-7"},"PeriodicalIF":2.2,"publicationDate":"2025-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143515930","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pneumocystis jirovecii pneumonia with use of brentuximab vedotin in treatment-naïve Hodgkin lymphoma.

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-02-24 DOI: 10.1080/10428194.2025.2470776

Ashwath Gurumurthi, Lynnette Henshaw, Lorenzo Falchi, Alison Moskowitz, Ariela Noy, Susan Seo, Robert Stuver

引用次数: 0

Clinical characteristics and disease outcomes of primary bone lymphoma in the rituximab era: a retrospective study from the Princess Margaret Cancer Center, Toronto, Canada.

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-02-21 DOI: 10.1080/10428194.2025.2467801

Chathuri Abeyakoon, Esther Ting, Sahar Khan, Manjula Maganti, Sita Bhella, Michael Crump, David Hodgson, Robert Kridel, Vishal Kukreti, John Kuruvilla, Abi Vijenthira, Chloe Yang, Danielle Rodin, Richard Tsang, Anca Prica

引用次数: 0

Resistance mechanisms and approach to chronic lymphocytic leukemia after BTK inhibitor therapy.

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-02-19 DOI: 10.1080/10428194.2025.2466101

Christine Gruessner, Adrian Wiestner, Clare Sun

{"title":"Resistance mechanisms and approach to chronic lymphocytic leukemia after BTK inhibitor therapy.","authors":"Christine Gruessner, Adrian Wiestner, Clare Sun","doi":"10.1080/10428194.2025.2466101","DOIUrl":"https://doi.org/10.1080/10428194.2025.2466101","url":null,"abstract":"Bruton tyrosine kinase (BTK), an essential component of the B-cell receptor (BCR) signaling pathway, is a validated target in chronic lymphocytic leukemia. Ibrutinib, acalabrutinib, and zanubrutinib are covalent BTK inhibitors (cBTKi) that bind to residue C481, leading to sustained target inhibition. A significant proportion of patients develop resistance to continuous cBTKi therapy, predominantly via mutations in BTK and its immediate downstream effector, PLCG2. The noncovalent BTKi pirtobrutinib does not require binding to C481 and can restore BTK inhibition after progression on a cBTKi. However, non-C481 BTK mutations conferring resistance to pirtobrutinib have been identified. Furthermore, the scaffolding function of BTK, activation of bypass signaling pathways, and the tumor microenvironment may contribute to BTKi resistance. Targeting BTK for degradation is an emerging strategy that appears effective against multiple BTK mutations, and inhibitors of downstream BCR signaling proteins are under development. This review addresses BTKi resistance mechanisms and therapeutic approaches after cBTKi failure.","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1-13"},"PeriodicalIF":2.2,"publicationDate":"2025-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143458613","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Mutational landscape of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) involving the central nervous system.

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-02-18 DOI: 10.1080/10428194.2025.2452341

Anna Shestakova, Nahideh Haghighi, Ying Zhang, Jana Tarabay, Mark G Evans, Anton Burtsev, Jefferson Y Chan, Ashley Gamayo, Xiaohui Zhao, Susan O'Brien, Fabiola Quintero-Rivera, Sherif A Rezk

引用次数: 0

High burden and poor outcomes of myelodysplastic neoplasms (MDS) in the real-world: a 10-year audit of three Australian hospitals.

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-02-18 DOI: 10.1080/10428194.2025.2467783

Zoe Loh, Michael Ashby, Marzia Rahman, Evangeline Y Wong, Doen Ming Ong, Susan Morgan, Chong Chyn Chua

引用次数: 0